|
LRCH1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.92360000150771E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.66450000005369E-06 |
| Normal-vs-Stage2 |
4.20079999996492E-06 |
| Normal-vs-Stage3 |
6.2840999959235E-08 |
| Normal-vs-Stage4 |
1.62961999999878E-05 |
| Stage1-vs-Stage2 |
1.596410E-01 |
| Stage1-vs-Stage3 |
2.383600E-02 |
| Stage1-vs-Stage4 |
2.189000E-01 |
| Stage2-vs-Stage3 |
7.888600E-01 |
| Stage2-vs-Stage4 |
8.693800E-01 |
| Stage3-vs-Stage4 |
6.506200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.07179999986329E-07 |
| Normal-vs-AfricanAmerican |
5.156500E-03 |
| Normal-vs-Asian |
3.617800E-04 |
| Caucasian-vs-AfricanAmerican |
5.910200E-01 |
| Caucasian-vs-Asian |
7.514800E-01 |
| AfricanAmerican-vs-Asian |
7.904200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.84850000031867E-07 |
| Normal-vs-Female |
6.80620000359511E-08 |
| Male-vs-Female |
3.705400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.70359999999548E-05 |
| Normal-vs-Age(41-60Yrs) |
4.37730000024672E-08 |
| Normal-vs-Age(61-80Yrs) |
1.64150000259156E-08 |
| Normal-vs-Age(81-100Yrs) |
2.249600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.046790E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.001700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.176200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.967400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.701400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.322000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.072600E-01 |
| Classical-VS-Follicular |
3.665600E-02 |
| Classical-VS-Other |
5.556800E-01 |
| Classical-VS-Normal |
1.99850000004442E-06 |
| Tall-VS-Follicular |
9.323400E-01 |
| Tall-VS-Other |
9.544000E-01 |
| Tall-VS-Normal |
1.010860E-04 |
| Follicular-VS-Other |
9.171600E-01 |
| Follicular-VS-Normal |
1.99250000054718E-07 |
| Other-VS-Normal |
2.827900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.83530002306753E-09 |
| Normal-vs-N1 |
1.78092999999491E-05 |
| N0-vs-N1 |
8.878000E-01 |
|
|
